You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 20, November 23/30, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Medical Practice
 •Health Policy
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Drug Prices and Value for Money

The Australian Pharmaceutical Benefits Scheme

David A. Henry, MB, FRCP; Suzanne R. Hill, MBBS, PhD, FAFPHM; Anthony Harris, MA, MSc

JAMA. 2005;294:2630-2632.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, Pearson and Rawlins1 describe the work of the National Institute for Health and Clinical Excellence (NICE), the main health technology assessment agency in the United Kingdom. NICE provides comprehensive advice, including assessment of efficacy and comparative cost-effectiveness of medical interventions and publishes clinical guidelines.2 This ambitious project is the most prominent and far reaching of a number of international initiatives, including health technology assessment programs in Canada and Spain3-4 and pharmaceutical cost-effectiveness evaluations linked to reimbursement decisions in Australia, the Netherlands, and Canada.5-7 The relevance to the United States has increased with the Medicare Prescription Drug Improvement and Modernization Act of 2003.8 This act introduces a voluntary program of prescription drug coverage but the US government will not get directly involved in price negotiation, leaving implementation of the drug . . . [Full Text of this Article]

Australian Pharmaceutical Benefits Scheme

Independence From Government

Relationship With the Pharmaceutical Industry

Transparency

Methodology

Cost-effectiveness Ratios and Budgets

Criticisms

Author Affiliations: School of Medicine and Public Health, University of Newcastle, New South Wales (Drs Henry and Hill) and Centre for Health Economics, Monash University, Victoria (Dr Harris), Australia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Cost-effectiveness and Resource Allocation
Joshua P. Cohen
JAMA. 2006;295(23):2723.
EXTRACT | FULL TEXT  

Cost-effectiveness and Resource Allocation—Reply
Anthony Harris, Suzanne R. Hill, and David A. Henry
JAMA. 2006;295(23):2723-2724.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Quality, Innovation, and Value for Money: NICE and the British National Health Service
Steven D. Pearson and Michael D. Rawlins
JAMA. 2005;294(20):2618-2622.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Controversies in Using Lapatinib at Reduced Dosage With Food
Trippoli
JCO 2007;25:5333-5333.
FULL TEXT  

The Value Meal: Effect of Food on Lapatinib Bioavailability
Rahman et al.
JCO 2007;25:5333-5334.
FULL TEXT  

Simplified Pharmacoeconomics of Critical Care and Severe Sepsis
Ernst et al.
J Intensive Care Med 2007;22:283-293.
ABSTRACT  

Medicare And Cost-Effectiveness Analysis: Time To Ask The Taxpayers
Gold et al.
Health Aff (Millwood) 2007;26:1399-1406.
ABSTRACT | FULL TEXT  

Linking Cost Sharing to Value: An Unrivaled Yet Unrealized Public Health Opportunity
Braithwaite and Rosen
ANN INTERN MED 2007;146:602-605.
ABSTRACT | FULL TEXT  

Cost-effectiveness and Resource Allocation
Cohen
JAMA 2006;295:2723-2723.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.